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 Abstract 
Hematopoietic cell transplantation (HCT) is frequently complicated by graft-versus-host 
disease (GVHD).  During the past three decades, experimental studies and clinical 
observations have elucidated the pathophysiology of acute GVHD, but the biology of 
chronic GVHD is much less well understood. Recommendations of the NIH Consensus 
Development Project on Criteria for Clinical Trials in Chronic GVHD have begun to 
standardize the diagnosis and clinical assessment of the disease. These criteria have 
emphasized the importance of qualitative differences, as opposed to time of onset after 
HCT, in making the distinction between acute and chronic GVHD. Experimental studies 
have generated at least four theories to explain the pathophysiology of chronic GVHD. 
These theories include 1) thymic damage and defective negative selection of T cells 
generated from marrow progenitors after HCT, 2) aberrant production of transforming 
growth factor-β, 3) auto-antibody production, and 4) deficiency of T-regulatory cells. 
Recent studies in humans have corroborated a possible role for each of these 
mechanisms in humans. No animal model fully replicates all of the features of chronic 
GVHD in humans, and it appears likely that multiple biological mechanisms account for the 
diverse features the disease. Chronic GVHD may represent a “syndrome” with diverse 
causes among individual patients. In the future, it might become possible to tailor specific 
therapeutic interventions for patients as individually needed for each distinct 
pathophysiologic mechanism involved in development of the disease.
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Clinical presentation and significance of chronic GVHD   
Chronic GVHD is a pleiomorphic syndrome with onset generally occurring between 3 and 
24 months after allogeneic hematopoietic cell transplantation (Table 1).1  The highly 
variable clinical manifestations of chronic GVHD frequently involve the skin, liver, eyes, 
mouth, upper respiratory tract, esophagus, and less frequently involve serosal surfaces, 
lower gastrointestinal tract, female genitalia, and fascia.2 The biological mechanisms 
leading to chronic GVHD are not as well understood as those leading to acute GVHD. 
Although acute GVHD has been recognized as a risk factor for chronic GVHD, not all 
cases of acute GVHD evolve into chronic GVHD, and chronic GVHD can develop in the 
absence of any prior overt acute GVHD. In the skin, the initial phase of chronic GVHD is 
characterized by an intense mononuclear inflammatory infiltrate with destructive changes 
at the dermal-epidermal junction, accompanied by irregular acanthosis, hyperkeratosis or 
atrophy, progressing to dermal fibrosis and sclerosis.3 Other hallmarks include destruction 
of tubuloalveolar glands and ducts in the skin, salivary and lacrimal glands and respiratory 
epithelium, and destruction of bile ducts in the liver.   
 
Immune-mediated mechanisms of fibrosis   
Insight regarding the pathophysiology and immunobiology of chronic GVHD is limited. A 
wide variety of experimental models have indicated an association between type-2 
polarized immune responses and the development of fibrosis,4 and donor type 2 immune 
responses are required for induction of skin GVHD in mice.5 Complement factor 5 (C5) has 
been identified as a quantitative trait that modifies liver fibrosis in mice and humans,6 and 
C5b-9 complexes are deposited in the skin, liver, lung and kidney in mice with GVHD.7 C3 
is deposited at the dermal-epidermal junction in humans with chronic GVHD,8 but 
deposition of C5b-9 complexes has not been described.  
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Animal models of chronic GVHD 
At least four different hypotheses regarding the pathogenesis of chronic GVHD have 
emerged from studies with animal models. One hypothesis posits that chronic GVHD 
results from thymic damage caused by acute GVHD, resulting in failure to delete nascent 
T cells that recognize antigens on donor or recipient cells. A second hypothesis implicates 
a central role for TGF-β in the pathogenesis of the disease. A third hypothesis implicates B 
cells and antibody-mediated mechanisms in certain manifestations of the disease. Lastly, 
deficiency in the numbers or function of T-regulatory cells might contribute to the 
development of chronic GVHD.   
 The literature is confusing because the term “chronic GVHD” has been used to 
describe a syndrome of antibody-mediated glomerulonephritis that occurs when recipient 
B cells are activated by donor CD4 cells after transplantation of spleen cells from certain 
parental strains into non-irradiated F1 mice. The resulting nephrotic syndrome is more 
characteristic of lupus nephritis as opposed to chronic GVHD, although case reports have 
occasionally described nephrotic syndrome in patients with chronic GVHD.            
 Failure of negative selection in the thymus. Cutaneous changes of acute and chronic 
GVHD occur in H-2b MHC-identical transplants between LP and C57BL/6 (B6) mice. 
Parkman9 showed that clones from B6 recipients with chronic GVHD were all CD4+ and all 
showed IL-2-dependent proliferative responses specific for MHC class II I-Ab antigens 
expressed by both the donor and recipient. The observation that CD4+ clones from 
recipients with chronic GVHD showed specificity for I-Ab suggested that these cells had 
emerged from marrow progenitors that escaped negative selection in the thymus, and the 
observation that similar clones could be detected in mice with acute GVHD suggested that 
the processes responsible for generating such autoimmune clones begin early after 
transplantation.  
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 Acute GVHD causes severe histopathological damage in the thymus, including injury 
to medullary epithelial cells, effacement of the corticomedullary junction, disappearance of 
Hassal’s corpuscles and depletion of CD4+CD8+ cells.10 In the thymus, developing T cells 
that express receptors with high affinity for peptide-MHC complexes or “self”-antigens on 
adjacent cells are deleted. This process of negative selection occurs in the medulla and is 
mediated by marrow-derived dendritic cells and thymic medullary epithelial cells. Negative 
thymic selection among T cells developing in mice with GVHD is impaired,11 and the T 
cells developing in mice with GVHD are pathogenic. Zhang et al.12 showed that dendritic 
cells were depleted in the thymus of B6 mice with acute GVHD caused by donor C3H.SW 
CD8 cells. The resulting thymic damage allowed the development of CD4 cells that 
responded vigorously to recipient B6 alloantigens. These CD4 cells caused chronic GVHD 
when they were adoptively transferred into irradiated secondary B6 recipients. 
Administration of keratinocyte growth factor (KGF) at the time of the transplant enhanced 
reconstitution of dendritic cells in the thymus, and the CD4 cells that emerged from KGF-
treated recipients did not cause GVHD in secondary B6 recipients.12  
 Zhang et al.12 also showed that donor-derived C3H.SW CD4 cells from B6 recipients 
with GVHD caused acute hepatic and intestinal GVHD when they were adoptively 
transferred into irradiated secondary C3H.SW recipients. Further evidence for 
“autoimmune” recognition among T cells developing in mice with GVHD was reported by 
Tivol et al.13 in experiments where adoptively transferred spleen cells from B6 → BALB/c 
chimeras with GVHD were adoptively transferred into nonirradiated secondary 
immunodeficient B6 or BALB/c recipients. Cells from the chimeras caused colitis in 
secondary B6 recipients but not in BALB/c recipients. In a different approach, several 
groups have shown that transplantation of MHC-class II-deficient marrow into wild-type 
recipients of the same strain causes autoimmune damage in the skin,14 liver and 
 6
intestines.15 Thymectomy prevented the disease, and adoptive transfer of CD4+ cells 
caused acute GVHD in irradiated secondary recipients of the same strain.    
 In a variation of the same approach, Sakoda et al.16 found that irradiated C3H (H-2k) 
recipients reconstituted with T cell-depleted marrow from MHC-class II-deficient B6 (H-2b) 
donors developed a disease with clinical and histopathological features characteristic of 
chronic GVHD, including epidermal atrophy, follicular dropout, fat loss, dermal fibrosis, bile 
duct loss, with inflammation, atrophy and fibrosis of acinar tissue in the salivary glands. 
Thymectomy prevented the disease, and the chimeric CD4 cells proliferated in response to 
donor-type B6 antigen-presenting cells (APCs) but not in response to recipient-type C3H 
APCs. Adoptive transfer of chimeric CD4 cells in the presence of B6 APCs caused chronic 
GVHD in irradiated secondary C3H recipients. In irradiated secondary B6 recipients, 
however, the adoptively transferred CD4 cells caused acute GVHD.  
 These results are consistent with those of an earlier study suggesting that CD4 cells 
cause acute GVHD when they recognize antigens expressed by recipient epithelial tissues 
but cause chronic GVHD when they recognize antigens on marrow-derived cells but not on 
epithelial tissues.17 In these models, the acute or chronic nature of GVHD appears to be 
dictated respectively by the presence or absence of the recognized antigens on epithelial 
cells of the recipient. Similar experiments have been done with B6 donors and MHC-
mismatched BALB/c or MHC-matched BALB.B recipients. Irradiated secondary BALB/c 
recipients developed acute GVHD,18 while secondary BALB.B recipients developed 
chronic GVHD19 after adoptive transfer of CD4 cells from chimeric donors with GVHD. 
Hence, an absence of the recognized antigens on recipient epithelial cells does not 
entirely explain the development of chronic GVHD.  
 Further work is needed to define the B6 antigens that stimulate proliferation of donor 
CD4 cells in the model described by Sakoda et al.16 In principle, the CD4 cells that develop 
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in the chimeras are positively selected by thymic cortical epithelial cells of the C3H 
recipient and negatively selected by MHC class I-positive B6 APCs and by recipient C3H 
epithelial cells in the thymic medulla. Although the donor-derived CD4 cells that escape 
MHC-class II-specific negative selection respond to wild type B6 APCs in vitro, the B6-
derived APCs in the primary recipients do not express MHC-class II molecules and would 
not be expected to stimulate donor-derived CD4 cells in vivo. Evidence from at least one 
study has suggested that the CD4 cells escaping negative selection in the thymus respond 
to MHC class I antigens.20   
 Taken together, the experiments with mice demonstrate that acute GVHD impairs 
negative selection of T cells in the thymus and that CD4 cells recognizing donor or 
recipient alloantigens can cause a syndrome with remarkable similarity to chronic GVHD. 
Further work is needed to determine whether these observations have relevance for 
chronic GVHD in humans. As reported by Tsoi et al.21 in 1980, donor-derived T cells from 
patients showed proliferative responses after stimulation with cells from HLA-identical 
sibling recipients in 14 of 22 (64%) cases with chronic GVHD and in only 1 of 12 cases 
without chronic GVHD (Table 2). Responses after stimulation with recipient cells could not 
be explained by progeny of mature T cells in the graft, since T cells from patients with 
acute GVHD did not respond after stimulation with recipient cells. The presence of 
alloreactive T cells in these patients suggests an impairment of negative selection by 
thymic medullary epithelial cells of the recipient. Responses after stimulation with donor 
cells were observed 7 of 22 cases (32%) without chronic GVHD and in only 1 of 12 cases 
without chronic GVHD. In all but one of these 8 cases, responses were also observed after 
stimulation with recipient cells. These results suggest that the primary defect associated 
with chronic GVHD in humans is an impairment of negative selection mediated by 
medullary thymic epithelial cells, with or without concomitant impairment of negative 
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selection mediated by donor-derived dendritic cells. It seems unlikely that this mechanism 
can account for all cases, however, since donor-derived cells from 7 of the 22 patients with 
chronic GVHD showed no measurable proliferative response after stimulation with either 
recipient or donor cells.                         
 Role of TGF-β. A syndrome characteristic of chronic GVHD develops after 
transplantation of B10.D2 lymphoid cells into irradiated BALB/c recipients.22 Skin changes 
include a mononuclear infiltrate deep in the dermis, loss of dermal fat, increased collagen 
deposition, and “dropout” of dermal appendages such as hair follicles, but in distinction to 
findings in acute GVHD, apoptosis of basal epithelial cells at the dermal-epidermal junction 
does not occur. Skin changes begin as early as day 11, and cutaneous fibrosis is apparent 
as early as day 21. Deposits of IgG, IgA and IgM appear at the dermal epidermal junction 
in this model.23 Additional features of the disease in this model include inflammation and 
fibrosis in salivary and lacrimal glands, sclerosing cholangitis, progressive renal and 
gastrointestinal fibrosis, and development of anti-Scl-70 antibody.24     
 Naïve donor CD4 cells initiate the disease in this strain combination,25,26 and the 
dermal infiltrate is comprised of T cells, monocytes and macrophages.27 Antigen 
presenting cells of either the donor or recipient are sufficient to initiate the disease, and 
costimulation of donor T cells through CD80 or CD86 on APCs is necessary in order to 
induce chronic GVHD.28 In this model, costimulation of donor CD4 cells through CD40 on 
APCs is necessary to induce intestinal disease but not skin disease. T cells and 
macrophages in the skin express TGF-β1 but not TGF-β2 or TGF-β3 mRNA.29 Microarray 
analysis also showed upregulated expression of type 1 (interferon-γ) and type 2 (IL-6, IL-
10 and IL-13) cytokines, chemokines, and a variety of growth factors and cell adhesion 
molecules in recipients with chronic GVHD as compared to recipients without chronic 
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GVHD.30 Administration of a neutralizing antibody against TGF-β prevented or reduced 
virtually all cutaneous manifestations of chronic GVHD, including cellular infiltration, 
immune cell activation, thickening and fibrosis.27 In contrast, neutralization of TGF-β by 
administration of latency-associated peptide prevented thickening and fibrosis, but did not 
prevent influx of T cells and monocytes or immune cell activation in the skin.31   
 Cutaneous manifestations of chronic GVHD develop after transplantation of B10.D2 
spleen cells into MHC-matched (H-2d) BALB/c recipients but not after transplantation of 
B10 spleen cells into MHC-matched (H-2b) BALB.B recipients or after transplantation of 
B10.BR spleen cells into MHC-matched (H-2k) BALB.K recipients (Table 3).32 In each of 
these combinations, the background genes of the donor are of B10 origin, while those of 
the recipient are of BALB origin, and the combinations differ from each other only in the 
MHC. These observations were interpreted as indicating that H-2d MHC class II molecules 
(I-Ad or I-Ed) could present minor antigen peptides derived from BALB skin to CD4 cells of 
B10 donors, while H-2b and H-2k class II molecules could not. Another explanation for this 
observation could be related to a polymorphism in the TNF-α gene, which is located in the 
MHC.33 Expression of TNF-α is reduced in H-2d mice as compared to H-2b or H-2k mice. 
Since TNF-α is a potent inhibitor of fibrosis induced by TGF-β, it has been proposed that 
the fibrosis observed with B10.D2 donors and BALB/c recipients might be related to an 
inability of cutaneous CD4 cells to produce TNF-α.34   
 Attempts to prevent or treat chronic GVHD through direct or indirect manipulation of 
TGF-β may encounter unexpected complexity. For example, Asai et al.35 showed that 
activated donor NK cells could attenuate the severity of acute GVHD through a TGF-β-
dependent mechanism.  TGF-β has a non-redundant, essential role in limiting T cell and 
NK cell responses, and TGF-β-deficient mice develop an early onset lethal autoimmune 
disease.36 The ability of TGF-β neutralization to prevent or treat chronic GVHD may 
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depend on the context in which the disease develops. Treatment of B10.D2 donors with G-
CSF exacerbates the severity of skin GVHD in sublethally irradiated BALB/c recipients. 
Donor T cells are required for the development of GVHD, but the severity of cutaneous 
sclerosis is determined by the non-T cell fraction of grafts from G-CSF-treated donors.37 In 
this model, neutralization of TGF-β from day 0 – 42 had no effect on manifestations of 
GVHD in the skin, liver or gastrointestinal tract, but neutralization of TGF-β beginning on 
day 14 appeared to attenuate progression of the disease to some extent in the skin and 
gastrointestinal tract, but not the liver.38 Neutralization of TGF-β after transplantation 
exacerbated acute GVHD by interfering with the regulatory effects of TGF-β on 
proliferation of donor T cells stimulated by recipient alloantigens. Finally, since TGF-β 
induces Foxp3 expression and T-regulatory function in CD4+CD25- precursors,39 TGF-β 
neutralization could exacerbate GVHD by interfering with development of T regulatory 
cells.         
The role of TGF-β in human chronic GVHD has not been defined. Results of one study 
showed elevated serum levels of TGF-β in patients with chronic GVHD as compared to 
patients without chronic GVHD.40 The interpretation of these results is complicated, since 
assays were carried out not with plasma, but with serum, which contains large amounts of 
TGF-β released from platelets during clotting. Gene expression studies have shown that 
increased TGF-β signaling in CD4 cells and CD8 cells was associated with a reduced risk 
of chronic GVHD in humans.41 These data might appear to conflict with results from 
experiments with B10.D2 donors and BALB/c recipients, but 4 of the 5 TGF-β pathway 
genes that were examined also showed increased expression associated with a 
decreased risk of acute GVHD. The association of increased TGF-β activity with a reduced 
 11
risk of chronic GVHD might result from a decreased risk of acute GVHD, since acute 
GVHD is a well-recognized risk factor for chronic GVHD.  
Established chronic GVHD induced by B10.D2 T cells in BALB/c recipients can be 
reversed by administration of an agonistic CD137-specific antibody, but administration of 
this antibody at the time of the transplant exacerbated the severity of acute GVHD.42 
Administration of agonistic CD137-specific antibody has been used successfully to treat 
CD4-mediated autoimmune diseases in variety of experimental models. Clinical trials will 
be needed to determine the safety and efficacy of this approach for treatment of chronic 
GVHD in humans.       
 Role of B cells. Deposition of antibody at the junction between the dermis and 
epidermis has been demonstrated in both murine models23 and in humans8 with chronic 
GVHD. Both euthymic and athymic BALB/c recipients developed high levels of double 
strand DNA-specific IgG1 and IgG2a autoantibodies in the serum, cutaneous sclerosis, 
and glomerulonephritis with proteinuria, beginning within the first 2 weeks after 
transplantation of spleen cells from DBA/2 (H-2d) donors.43 Induction of disease required 
both donor CD4+CD25- T cells and donor B cells. In the absence of donor B cells, donor 
CD4 cells caused acute GVHD without cutaneous sclerosis or glomerulonephritis. The 
relevance of this model for human chronic GVHD could be questioned, since double-
strand DNA-specific autoantibodies, immune complex glomerulonephritis and proteinuria 
are characteristic of systemic lupus but rarely occur in patients with chronic GVHD.44   
 Several lines of evidence suggest that B cells are likely to have some role in the 
pathogenesis of chronic GVHD in humans. First, anecdotal experience and phase 2 
studies have shown clinical improvement in some patients with chronic GVHD after 
administration of a CD20-specific antibody.45 Second, biomarker studies have shown 
enhanced CD86 expression after TLR9 stimulation of B cells from patients with chronic 
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GVHD, as compared to those from controls.46 Third, patients with chronic GVHD have high 
levels of B cell activating factor, which promotes the survival and differentiation of 
activated B cells.47 Finally, agonistic antibodies against platelet-derived growth factor 
receptor (PDGFR) were detected in serum from each of 22 patients with clinical extensive 
chronic GVHD but not in serum from any of 17 patients without chronic GVHD.48 These 
antibodies induce tyrosine phosphorylation of PDGFR, accumulation of reactive oxygen 
species, and stimulation of type 1 collagen gene expression by fibroblasts, through a Ras 
and ERK1/2-dependent signaling pathway. These results suggest novel approaches for 
treatment of chronic GVHD, since ligand-induced phosphorylation of the PDGFR is 
susceptible to inhibition by certain tyrosine-kinase inhibitors, including imatinib. 
 Role of T regulatory cells. Acute GVHD not only impairs negative selection of T cells in 
the thymus, as discussed above, but also impairs development of T regulatory cells,18 
which might otherwise prevent the development of chronic GVHD. Anderson et al.49 
showed that donor or recipient-derived T regulatory cells could prevent GVHD caused by 
B10.D2 CD4 cells in BALB/c recipients, and Zhang et al.43 similarly showed that donor-
derived T regulatory cells could prevent GVHD caused by DBA/2 CD4 cells and B cells in 
BALB/c recipients. More impressively, Fujita et al.50 showed that recipient-derived 
regulatory dendritic cells cultured in medium containing GM-CSF, IL-10, and TGF-β and 
then matured by exposure to lipopolysaccharide were not only able to prevent GVHD 
caused by B10.D2 CD4 cells in BALB/c recipients but were also able to reverse previously 
established GVHD.  
 Conflicting results have been reported with respect to the role of T-regulatory cells in 
preventing the development of chronic GVHD in humans. Results of at least two studies 
suggested that the presence of increased numbers of T regulatory cells in the blood was 
associated with a decreased risk of chronic GVHD,51,52 but these results were not 
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confirmed by two other studies.53,54 The most persuasive results emerged from a study by 
Rieger et al.,55 who showed that colonic mucosa from patients with acute or chronic GVHD 
contained very low numbers of T regulatory cells relative to the numbers of CD8 cells, 
whereas specimens from patients with cytomegalovirus infection or diverticulitis contained 
much higher numbers of T regulatory cells relative to the numbers of CD8 cells.       
  
1B1BFuture prospects 
 The results summarized above raise more questions than answers and leave the 
impression that no animal model fully replicates all of the features of chronic GVHD in 
humans, and more importantly, that no single biological mechanism is likely to account for 
the diverse features of chronic GVHD in humans. In the future, it might become possible to 
tailor treatment for specific abnormalities that contribute to the disease in each individual 
patient. The disease is clearly initiated by donor T cells that recognize recipient 
alloantigens, since the incidence of chronic GVHD can be decreased by exhaustive 
depletion of T cells from the graft. Evidence from animal models has clearly demonstrated 
that acute GVHD can cause defects in thymic negative selection, allowing the 
development of alloreactive T cells that cause chronic GVHD. Preliminary results have 
suggested that administration of KGF could potentially be used to prevent or treat chronic 
GVHD that results from this type of mechanism. T cells and B cells can also contribute to 
pathogenesis of the disease through mechanisms that do not necessarily depend on prior 
acute GVHD or thymic dysfunction. It seems likely that binding of agonistic antibodies to 
cell surface molecules other than PDGFR might account for certain manifestations of 
chronic GVHD. If so, then a range of small molecule inhibitors of intracellular signal 
transduction could one day be used to treat the disease. More importantly, elucidation of 
the mechanisms responsible for generating pathogenic autoantibodies could provide a 
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basis for development of methods to prevent chronic GVHD. Finally, development of 
methods for ex-vivo expansion of T regulatory cells or for improving the generation, 
survival and function of these cells in vivo could be used to prevent or reverse chronic 
GVHD caused by deficits in the numbers or function of T regulatory cells.     
 15
Acknowledgements 
This work was supported by grant CA 98906 from the National Cancer Institute, National 
Institutes of Health, U.S. Department of Health and Human Services.  
 16
References 
 1.  Lee SJ, Vogelsang G, Flowers MED:  Chronic graft-versus-host disease. Biol Blood 
Marrow Transplant 2003; 9: 215-233. 
 2.  Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien 
J, Prezepiorka D , Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, 
Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, 
Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers MED:  National 
Institutes of Health consensus development project on criteria for clinical trials in 
chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report.  
Biol Blood Marrow Transplant 2005; 11: 945-956. 
 3.  Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, Moresi JM, 
Greenson J, Janin A, Martin PJ, McDonald G, Flowers MED, Turner M, Atkinson J, 
Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH, Rashid A, 
Hiatt K, Couriel D, Schultz K, Hymes S, Vogelsang GB:  Histopathologic diagnosis of 
chronic graft-versus-host disease: National Institutes of Health consensus 
development project on criteria for clinical trials in chronic graft-versus-host disease: 
II. Pathology Working Group report. Biol Blood Marrow Transplant 2006; 12: 31-47. 
 4.  Wynn TA:  Fibrotic disease and the T(H)1/T(H)2 paradigm (Review). Nature Reviews 
2004; Immunology. 4: 583-594. 
 5.  Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M:  Th1 and Th2 mediate acute 
graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000; 
105: 1289-1298. 
 6.  Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, 
Schirin-Sokhan R, Wilkens G, Geier A, Lorenzen J, Kohl J , Gressner AM, Matern S,  
 17
Lammert F:  Complement factor 5 is a quantitative trait gene that modifies liver 
fibrogenesis in mice and humans. Nat Genet 2005; 37: 835-843. 
 7.  Niculescu F, Niculescu T, Nguyen P, Puliaev R, Papadimitriou JC, Gaspari A, Rus H, 
Via CS:  Both apoptosis and complement membrane attack complex deposition are 
major features of murine acute graft-vs.-host disease. Exp Mol Pathol 2005; 79: 136-
145. 
 8.  Tsoi M-S, Storb R, Jones E, Weiden PL, Shulman H, Witherspoon R, Atkinson K, 
Thomas ED:  Deposition of IgM and complement at the dermo-epidermal junction in 
acute and chronic cutaneous graft-vs-host disease in man. J Immunol 1978; 120: 
1485-1492. 
 9.  Parkman R:  Clonal analysis of murine graft-vs-host disease.  I. Phenotypic and 
functional analysis of T lymphocyte clones. J Immunol 1986; 136: 3543-3548. 
 10.  Ghayur T, Seemayer TA, Xenocostas A, Lapp WS:  Complete sequential 
regeneration of graft-vs.-host-induced severely dysplastic thymuses. Implications for 
the pathogenesis of chronic graft-vs.-host disease. Am J Pathol 1988; 133: 39-46. 
 11.  Morohashi T, Ogasawara K, Kitaichi N, Iwabuchi K, Onoe K:  Abrogation of negative 
selection by GVHR induced by minor histocompatibility antigens or H-2D antigen 
alone. Immunobiology 2000; 202: 268-279. 
 12.  Zhang Y, Hexner E, Frank D, Emerson SG:  CD4+ T cells generated de novo from 
donor hemopoietic stem cells mediate the evolution from acute to chronic graft-
versus-host disease. J Immunol 2007; 179: 3305-3314. 
 13.  Tivol E, Komorowski R, Drobyski WR:  Emergent autoimmunity in graft-versus-host 
disease. Blood 2005; 105: 4885-4891. 
 18
 14.  Marguerat S, MacDonald HR, Kraehenbuhl JP, van Meerwijk JP:  Protection from 
radiation-induced colitis requires MHC class II antigen expression by cells of 
hemopoietic origin.  J Immunol 1999; 163: 4033 -4040. 
 15.  Teshima T, Reddy P, Liu C, Williams D, Cooke KR, Ferrara JL:  Impaired thymic 
negative selection causes autoimmune graft-versus-host disease. Blood 2003; 102: 
429-435. 
 16.  Sakoda Y, Hashimoto D, Asakura S, Takeuchi K, Harada M, Tanimoto M, Teshima T:  
Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. 
Blood 2007; 109: 1756-1764. 
 17.  Jones SC, Murphy GF, Friedman TM, Korngold R:  Importance of minor 
histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-
mediated graft-versus-host disease model. J Clin Invest 2003; 112: 1880-1886. 
 18.  Chen X, Vodanovic-Jankovic S, Johnson B, Keller M , Komorowski R, Drobyski WR:  
Absence of regulatory T cell control of TH1 and TH17 cells is responsible for the 
autoimmune-mediated pathology in chronic graft versus host disease. Blood 2007; 
110: 3804-3813. 
 19.  Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG:  Alloreactive memory T cells are 
responsible for the persistence of graft-versus-host disease. J Immunol 2005; 174: 
3051-3058. 
 20.  Trobonjaca Z, Leithauser F, Moller P, Bluethmann H, Koezuka Y, MacDonald HR, 
Reimann J:  MHC-II-independent CD4+ T cells induce colitis in immunodeficient 
RAG-/- hosts. J Immunol 2001; 166: 3804-3812. 
 21.  Tsoi M-S, Storb R, Dobbs S, Medill L, Thomas ED:  Cell-mediated immunity to non-
HLA antigens of the host by donor lymphocytes in patients with chronic graft-vs-host 
disease. J Immunol 1980; 125: 2258-2262. 
 19
 22.  Jaffee BD, Claman HN:  Chronic graft-versus-host disease (GVHD) as a model for 
scleroderma. I. Description of model systems. Cell Immunol 1983; 77: 1-12. 
 23.  Claman HN, Jaffee BD, Huff JC, Clark RA:  Chronic graft-versus-host disease as a 
model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in 
the skin and fibrosis. Cell Immunol 1985; 94: 73-84. 
 24.  Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD:  A modified model of graft-
versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of 
the human disease. Arthritis Rheum 2004; 50: 1319-1331. 
 25.  Korngold R, Sprent J:  Variable capacity of L3T4+ T cells to cause lethal graft-versus-
host disease across minor histocompatibility barriers in mice. J Exp Med 1978; 165: 
1552-1564. 
 26.  Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, Shlomchik WD:  
Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003; 
112: 101-108. 
 27.  McCormick LL, Zhang Y, Tootell E, Gilliam AC:  Anti-TGF-beta treatment prevents 
skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model 
for human scleroderma. J Immunol 1999; 163: 5693-5699. 
 28.  Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ:  Distinct 
roles for donor- and host-derived antigen-presenting cells and costimulatory 
molecules in murine chronic graft-versus-host disease: requirements depend on 
target organ. Blood 2005; 105: 2227-2234. 
 29.  Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC:  Murine sclerodermatous 
graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, 
chemokines, and immune cell activation. J Immunol 2002; 168: 3088-3098. 
 20
 30.  Zhou L, Askew D, Wu C, Gilliam AC:  Cutaneous gene expression by DNA microarray 
in murine sclerodermatous graft-versus-host disease, a model for human 
scleroderma. J Invest Dermatol 2007; 127: 281-292. 
 31.  Zhang Y, McCormick LL, Gilliam AC:  Latency-associated peptide prevents skin 
fibrosis in murine sclerodermatous graft-versus-host disease, a model for human 
scleroderma. J Invest Dermatol  2003; 121: 713-719. 
 32.  Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD:  Target 
antigens determine graft-versus-host disease phenotype. J Immunol 2004; 173: 5467-
5475. 
 33.  Freund YR, Sgarlato G, Jacob CO, Suzuki Y, Remington JS:  Polymorphisms in the 
tumor necrosis factor alpha (TNF-alpha) gene correlate with murine resistance to 
development of toxoplasmic encephalitis and with levels of TNF-alpha mRNA in 
infected brain tissue. J Exp Med 1992; 175: 683-688. 
 34.  Askew D, Zhou L, Wu C, Chen G, Gilliam AC:  Absence of cutaneous TNFalpha-
producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial 
cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human 
scleroderma. J Invest Dermatol 2007; 127: 1905-1914. 
 35.  Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ:  
Suppression of graft-versus-host disease and amplification of graft-versus-tumor 
effects by activated natural killer cells after allogeneic bone marrow transplantation. J 
Clin Invest  1998; 101: 1835-1842. 
 36.  Rubtsov YP, Rudensky AY:  TGF-beta signaling in control of T-cell-mediated self-
reactivity (Review). Nat Rev Immunol 2007; 7: 443-453. 
 37.  MacDonald KP, Rowe V, Filippich C, Johnson D, Morris ES, Clouston AD, Ferrara JL, 
Hill GR:  Chronic graft-versus-host disease after granulocyte colony-stimulating 
 21
factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and 
differentiation. Biol Blood Marrow Transplant 2004; 10: 373-385. 
 38.  Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A, Kelly J, Ledbetter S, 
Clouston AD, Hill GR:  TGF-beta in allogeneic stem cell transplantation: friend or foe? 
Blood 2005; 106: 2206-2214. 
 39.  Fu S, Zhang N , Yopp AC, Chen D, Mao M, Chen D, Zhang H, Ding Y, Bromberg JS:  
TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J 
Transplant 2004; 4: 1614-1627. 
 40.  Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E:  Serum transforming growth 
factor-beta1 levels in bone marrow transplant recipients correlate with blood cell 
counts and chronic graft-versus-host disease. Transplantation 1999; 67: 59-65. 
 41.  Baron C, Somogyi R, Greller LD, Rineau V, Wilkinson P, Cho CR, Cameron MJ, 
Kelvin DJ, Chagnon P, Roy DC, Busque L, Sekaly RP, Perreault C:  Prediction of 
graft-versus-host disease in humans by donor gene-expression profiling. PLoS 
Medicine 2007; 4: e23- 
 42.  Kim J, Kim HJ , Park K, Kim J, Choi HJ, Yagita H, Nam SH, Cho HR, Kwon B:  
Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host 
disease. Blood 2007; 110: 776-782. 
 43.  Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, Strober S, Zeng D:  Donor 
CD4+ T and B cells in transplants induce chronic graft-versus-host disease with 
autoimmune manifestations. Blood 2006; 107: 2993-3001. 
 44.  Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E:  Autoimmunity after 
allogeneic bone marrow transplantation. Transplantation 1988; 46: 238-240. 
 45.  Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, 
Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz 
 22
J, Alyea E:  Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 
2006; 108: 756-762. 
 46.  She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z, Reid GS, Wall D, 
Goldman F, Schultz KR:  Altered Toll-like receptor 9 responses in circulating B cells 
at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow 
Transplant 2007; 13: 386-397. 
 47.  Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, Antin JH, 
Ritz J:  High levels of B-cell activating factor in patients with active chronic graft-
versus-host disease. Clin Cancer Res 2007; 13 : 6107-6114. 
 48.  Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, Moroncini G, 
Bacigalupo A, Leoni P, Avvedimento EV, Gabrielli A:  Stimulatory autoantibodies to 
PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 
2007; 110: 237-241. 
 49.  Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ:  
Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host 
disease. Blood 2004; 104: 1565-1573. 
 50.  Fujita S, Sato Y, Sato K, Eizumi K,  Fukaya T, Kubo M, Yamashita N, Sato K:  
Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease 
mediated through CD4+CD25+Foxp3+ regulatory T cells. Blood 2007; 110:3793-3803.  
 51.  Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, 
Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD:  Association of Foxp3 regulatory gene 
expression with graft-versus-host disease. Blood 2004; 104: 2187-2193. 
 52.  Zorn E, Kim HT, Lee SJ, Floyd BH,  Litsa D, Arumugarajah S, Bellucci R, Alyea EP, 
Antin JH, Soiffer RJ, Ritz J:  Reduced frequency of FOXP3+ CD4+CD25+ regulatory 
 23
T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903-
2911. 
 53.  Meignin V, de Latour RP, Zuber J, Regnault A, Mounier N, Lemaitre F, Dastot H, 
Itzykson R, Devergie A, Cumano A, Gluckman E, Janin A, Bandeira A, Socie G:  
Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the 
establishment of long-term tolerance after allogeneic stem cell transplantation. Exp 
Hematol 2005;  33: 894-900. 
 54.  Arimoto K, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T:  FOXP3 expression in 
peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-
versus-host disease after allogeneic stem cell transplantation. Int J Hematol 2007; 85: 
154-162. 
 55.  Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, Steiner B, Berg E, 
Miehlke S, Bornhauser M, Schneider T, Zeitz M, Stein H, Thiel E, Duchmann R, 
Uharek L:  Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and 
chronic GvHD. Blood 2006; 107: 1717-1723. 
 24
Table 1. Overview of Chronic GVHD
• Pleiomorphic syndrome
• Resembles autoimmune diseases
• Onset at 3 – 15 months after transplant
• 40 – 60% incidence among 3-month survivors
• Involvement of multiple organs
• Immune dysfunction with risk of infections
• 30-50% risk of transplant-related mortality
• Reduced risk of recurrent malignancy
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Table 2. Responses of T Cells from patients*
0 (0)8 (36)By recipient alone, n (%)
0 (0)7 (32)Neither, n (%)
1 (8)6 (27)By both, n (%)
0 (0)1 (5)By donor alone, n (%)
No (n = 12)Yes (n = 22)
Response after  
stimulation
Chronic GVHD
*adapted from reference 21
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Table 3. GVHD phenotypes, according to differences in MHC  
     
 TNF-α GVHD Phenotype 
Donor Recipient MHC Production Skin Systemic 
B10.D2 BALB/c H-2d Low Chronic None 
B10.BR BALB.K H-2k High Modified* Present 
B10 BALB.B H-2b High None Present 
B10 x B10.D2 BALB.B x BALB/c H-2b/d Intermediate   Chronic Present 
*less severe, especially for hair loss; adapted from reference 32 
 
